Recurrent mutations in the JAK–STAT, NF-κB, and B-cell receptor (BCR) pathways, including CD79B, MYD88, and CDKN2A deletions, have been identified as the defining characteristics of primary central nervous system lymphomas (15–17). This evidence concerns the gene BCR and primary central nervous system lymphoma.